For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the ...
Conestoga Capital Advisors, an asset management company, released its fourth-quarter 2024 investor letter. A copy of the ...
Here's our initial take on Vertex Pharmaceuticals' (NASDAQ: VRTX) fourth-quarter financial report. Key Metrics Metric Q4 2023 Q4 2024 Change vs. Expectations Revenue $2.52 billion $2.91 billion 16% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback